Myopia
A refractive error in which rays of light entering the EYE parallel to the optic axis are brought to a focus in front of the RETINA when accommodation (ACCOMMODATION, OCULAR) is relaxed. This results from an overly curved CORNEA or from the eyeball being too long from front to back. It is also called nearsightedness.
Subtype terms (1)
More specific conditions that are subtypes of Myopia in the MeSH hierarchy.
- Myopia, Degenerative
10 drugs (5 approved, 5 experimental)
Drugs by status
Phase 4 trials (13)
Phase 3 trials (6)
Phase 2 trials (12)
Organizations
Organization Involved with Phase 4 Indications (12)
- Bp Consulting, Inc
- Danbury Eye Physicians & Surgeons, PC
- Dr Salouti Eye Research Center
- Instituto de Olhos de Goiania
- Min-Sheng General Hospital
- National Yang-Ming University
- Ophthalmic Consultants of Long Island
- University of Tehran
- State University of New York
- Jiao Tong University
- University of New South Wales
- Shanghai Eye Disease Prevention and Treatment Center
Organization Involved with Phase 3 Indications (23)
- Regeneron
- Alcon
- Novartis
- Bayer
- Chengdu Kanghong Biotech Co.,Ltd.
- Eyenovia Inc.
- INC Research
- National Eye Institute (NEI)
- Jaeb Center for Health Research
- Johns Hopkins University
- Singapore National Eye Centre
- University of Waterloo
- Instituto Universitario de Oftalmobiología Aplicada
- University of California, Berkeley
- University of Freiburg
- University of Strasbourg
- University of Castilla-La Mancha
- University of Alabama, Birmingham
- Fondo de Investigacion Sanitaria
- Government of Singapore
- Nevakar, LLC
- Sydnexis, Inc.
- The V.P. Vyhodcev Eye Hospital
Organization Involved with Phase 2 Indications (14)
- Ocata Therapeutics
- Santen Inc.
- Mateon Therapeutics
- Region Syddanmark
- Aarhus University
- Ohio State University
- Queen's University, Belfast
- Trier Research Laboratories
- University of California, Los Angeles
- University of Copenhagen
- University of Missouri
- Sun Yat-Sen University
- Brien Holden Vision Institute
- Hai Eye Eye Care
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (8)